A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors

Completed · Phase 3 · Has a placebo group

Conditions studied: Colitis, Ulcerative

In brief

This Phase III, randomized, double-blind, parallel-grouped, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab in maintenance of remission in participants with moderately to severely active UC who are naive to TNF inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.

Key facts

Study ID

NCT02165215

Run by

Hoffmann-La Roche

People needed

359

Starts

2014-08-12

Expected to finish

2020-04-06

Last updated by the study team

2021-08-19

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of ulcerative colitis (UC) established at least 3 months prior to Day 1 by clinical and endoscopic evidence
• Moderately to severely active UC as determined by an MCS of 6-12 with an endoscopic subscore greater than or equal to (≥)2 as determined by the central reading procedure (endoscopy to be performed 4-16 days prior to Day 1), a rectal bleeding subscore ≥1, and a stool frequency subscore ≥1 during the screening period (prior to Day 1)
• Evidence of UC extending a minimum of 20 centimeters (cm) from the anal verge as determined by baseline endoscopy (flexible sigmoidoscopy or colonoscopy) performed during screening, 4-16 days prior to Day 1
• Naive to treatment with any anti-TNF therapy
• Participants must have had an inadequate response, loss of response, or intolerance to prior corticosteroid and/or immunosuppressant treatment
• Background regimen for UC may include oral 5-aminosalicylate (5-ASA), oral corticosteroids, budesonide, probiotics, azathioprine (AZA), 6-mercaptopurine (6-MP), or methotrexate (MTX) if doses have been stable during the screening period
• Use of highly effective contraception
• Must have received a colonoscopy within the past year or be willing to undergo a colonoscopy in lieu of a flexible sigmoidoscopy at screening

You may not qualify if…

• A history of or current conditions and diseases affecting the digestive tract, such as indeterminate colitis, suspicion of ischemic colitis, radiation colitis, or microscopic colitis, Crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, intestinal obstruction, toxic megacolon, or unremoved adenomatous colonic polyps
• Prior or planned surgery for UC
• Past or present ileostomy or colostomy
• Any prior treatment with etrolizumab or other anti-integrin agents (including natalizumab, vedolizumab, and efalizumab) as stated in the protocol
• Any prior treatment with anti-adhesion molecules (such as mucosal addressin cell adhesion molecule [MAdCAM-1])
• Any prior treatment with rituximab
• Any treatment with tofacitinib during screening
• Cogenital or acquired immune deficiency, chronic hepatitis B or C infection, human immunodeficiency virus (HIV) positive, or history of tuberculosis (active or latent)
• Evidence of or treatment for Clostridium difficile within 60 days prior to Day 1 or other intestinal pathogens within 30 days prior to Day 1
• History of recurrent opportunistic infections and/or severe disseminated viral infections
• History of organ transplant
• Any major episode of infection requiring treatment with intravenous (IV) antibiotics within 8 weeks prior to screening or oral antibiotics within 4 weeks prior to screening
• Received a live attenuated vaccine within 4 weeks prior to Day 1

Where it is running

• Clinical Applications Laboratories, Inc. — San Diego, California, United States
• University of California at San Francisco — San Francisco, California, United States
• Ventura Clinical Trials — Ventura, California, United States
• Peak Gastroenterology Associates; Gastroenterology — Colorado Springs, Colorado, United States
• Clinical Research of the Rockies — Lafayette, Colorado, United States
• West Central Gastroenterology d/b/a Gastro Florida — Clearwater, Florida, United States
• Regenerate Clinical Trials — Miami, Florida, United States
• IMIC, Inc — Miami Beach, Florida, United States
• Advanced Research Institute, Inc. — Trinity, Florida, United States
• Shafran Gastroenterology Center — Winter Park, Florida, United States
• Northwestern University-Feinberg School of Medicine; Division of Gastroenterology and Hepatology — Chicago, Illinois, United States
• Southwest Gastroenterology — Oak Lawn, Illinois, United States
• Aquiant Research — New Albany, Indiana, United States
• Louisiana Research Center, LLC — Shreveport, Louisiana, United States
• Commonwealth Clinical Studies — Brockton, Massachusetts, United States
• Henry Ford Health System — Detroit, Michigan, United States
• Center for Digestive Health — Troy, Michigan, United States
• University of Minnesota — Minneapolis, Minnesota, United States
• University of Mississippi Medical Center — Jackson, Mississippi, United States
• Ehrhardt Clinical Research, LLC — Belton, Missouri, United States
• Manhattan Clinical Research — New York, New York, United States
• Weill Cornell Medical College-New York Presbyterian Hospital — New York, New York, United States
• Asheville Gastroenterology Associates, P.A. — Asheville, North Carolina, United States
• UNC at Chapel Hill - Dpt of Family Medicine; Center for Functional GI and Motility Disorders — Chapel Hill, North Carolina, United States
• University of California, Irvine Medical Center — Orange, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.